-transparent.png){kind=logo}
The in vitro activity of ceftibuten was studied in 572 bacterial strains and was compared with the activity of other orally administered beta-lactams. Ceftibuten displayed high activity against the Enterobacteriaceae, generally being 16-fold more active than cefuroxime, cefaclor, cephalexin, or amoxicillin-clavulanic acid. Its activity was comparable to cefixime. There was little ceftibuten or cefixime activity against staphylococci (MIC90s greater than or equal to 64 micrograms/ml) and reduced activity against Streptococcus pneumoniae (MIC90, 16 micrograms/ml). Haemophilus influenzae and Neisseria spp. were highly susceptible to ceftibuten and cefixime. The protein binding of ceftibuten was 77%, and the primary target site was PBP 3. A high degree of stability to beta-lactamase hydrolysis was observed.
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
July 1967,
Applied microbiology,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
March 1969,
Applied microbiology,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
March 1996,
The Medical letter on drugs and therapeutics,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
October 1988,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
May 1991,
Pathologie-biologie,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
July 1999,
The Journal of antibiotics,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
September 1977,
Antimicrobial agents and chemotherapy,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
December 1988,
The Journal of antibiotics,
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
August 1991,
Journal of chemotherapy (Florence, Italy),
R Wise, and
J M Andrews, and
J P Ashby, and
D Thornber
September 1997,
The Annals of pharmacotherapy,
